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Background: Idiopathic normal pressure hydrocephalus (iNPH) is a treatable cause of dementia, gait disturbance,
and urinary incontinence in elderly patients with ventriculomegaly. Its unique morphological feature, called
disproportionately enlarged subarachnoid-space hydrocephalus (DESH), may also be a diagnostic feature.
Lipocalin-type prostaglandin D synthase (L-PGDS) is a major cerebrospinal fluid (CSF) protein produced by
arachnoid cells, and its concentration in the CSF is reportedly decreased in iNPH. L-PGDS acts as a prostaglandin
D2-producing enzyme and behaves as a chaperone to prevent the neurotoxic aggregation of amyloid beta (Aβ)
implicated in Alzheimer’s disease, a major comorbidity of iNPH. The aim of this study was to confirm the L-PGDS
decrease in DESH-type iNPH and to clarify its relationship with clinico-radiological features or other CSF biomarkers.
Methods: We evaluated 22 patients (age: 76.4 ± 4.4 y; males: 10, females: 12) referred for ventriculomegaly without
CSF pathway obstruction, and conducted a CSF tap test to determine the surgical indication. CSF concentrations of
L-PGDS, Aβ42, Aβ40, and total tau (t-tau) protein were determined using enzyme-linked immunosorbent assays.
Clinical symptoms were evaluated by the iNPH grading scale, mini-mental state examination, frontal assessment
battery (FAB), and timed up and go test. The extent of DESH was approximated by the callosal angle, and the
severity of parenchymal damage was evaluated by the age-related white matter change (ARWMC) score.
Results: L-PGDS and t-tau levels in CSF were significantly decreased in DESH patients compared to non-DESH
patients (p = 0.013 and p = 0.003, respectively). L-PGDS and t-tau showed a significant positive correlation (Spearman
r = 0.753, p < 0.001). Among the clinico-radiological profiles, L-PGDS levels correlated positively with age (Spearman
r = 0.602, p = 0.004), callosal angle (Spearman r = 0.592, p = 0.004), and ARWMC scores (Spearman r = 0.652,
p = 0.001), but were negatively correlated with FAB scores (Spearman r = 0.641, p = 0.004).
Conclusions: Our data support the diagnostic value of L-PGDS as a CSF biomarker for iNPH and suggest a possible
interaction between L-PGDS and tau protein. In addition, L-PGDS might work as a surrogate marker for DESH
features, white matter damage, and frontal lobe dysfunction.
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Table 1 Patient characteristics
DESH non-DESH p value
Gender (male/female) 4/6 6/6
Age (years) 75.7 ± 4.4 77 ± 9.3 0.17
Tap positive 8 5
Shunt operation 7 3
Shunt success 6 2
AChE inhibitor prescription 3 5
Opening CSF pressure (cmH2O) 14.8 ± 1.7 14.8 ± 1.3 0.99
Evans index (%) 34.5 ± 2.8 32.7 ± 4.3 0.27
Callosal angle (degrees) 79.9 ± 5.5 101.2 ± 4.3 0.01*
ARWMC 9.2 ± 1.6 13.3 ± 2.0 0.19
MMSE 22.5 ± 4.6 18.1 ± 6.4 0.05
FAB 11.4 ± 4.0 9.9 ± 4.0 0.27
TUG (s) 17.8 ± 0.8 29.8 ± 5.7 0.04*
TUG (step) 24.2 ± 0.6 38 ± 5.0 0.01*
iNPHGS 7.3 ± 0.9 9.1 ± 1.0 0.24
t-tau (pg/mL) 319.9 ± 31 546.2 ± 54 0.003*
Aβ42 (pM) 59.2 ± 7.5 57.2 ± 6.0 0.84
Aβ40 (pM) 1198 ± 76 1314 ± 45 0.19
L-PGDS (μg/mL) 14.4 ± 1.0 20.8 ± 2.0 0.01*
Data are numbers or the mean ± the standard deviation. iNPH: idiopathic
normal pressure hydrocephalus, DESH, disproportionately enlarged
subarachnoid-space hydrocephalus, AChE: acetylcholinesterase, ARWMC: age
related white matter change, MMSE: mini-mental state examination, FAB:
frontal assessment battery, TUG: timed up and go test, iNPHGS: iNPH grading
scale, t-tau: total tau, Aβ: amyloid beta, L-PGDS: lipocalin-type prostaglandin D
synthase. *: p < 0.05.
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Normal pressure hydrocephalus (NPH) is a cause of
treatable dementia, gait disturbance, and urinary incon-
tinence in elderly patients with ventriculomegaly. How-
ever, the diagnostic strategy is fairly anecdotal, and
ultimately dependent on successful cerebrospinal fluid
(CSF) shunt surgery, particularly for idiopathic NPH
(iNPH) [1,2]. Patients with several differential diagnoses
such as vascular dementia, Alzheimer’s disease (AD),
and other neurodegenerative disorders with lower body
Parkinsonism all have the above-mentioned symptoms.
Although the clinical features may be fairly nonspecific,
we must consider a CSF tap test when encountering eld-
erly patients with dilated cerebral ventricles [3]. Analysis
of CSF is sometimes helpful for estimating the underlying
intracranial processes [4]. In addition to the ventriculome-
galy and CSF profiles, a narrow callosal angle [5] and char-
acteristic patterns of uneven CSF distribution within the
subarachnoid space, defined as disproportionately en-
larged subarachnoid-space hydrocephalus (DESH) [6], are
helpful for diagnosis, and have been proposed as potential
iNPH-related features.
In this study, we analyzed the clinical, radiological, and
CSF profiles of 22 consecutive patients who were re-
ferred to our institute for possible iNPH. We found sig-
nificant differences in the arachnoidopathic marker
lipocalin-type prostaglandin D synthase (L-PGDS) be-
tween DESH and non-DESH patients. Moreover, we
found that this marker was correlated with the cognitive
profiles, neurodegenerative CSF markers, white matter
damage scores, and tight high convexity.
Methods
Patients
Twenty-two patients (mean age 76.4 ± 4.4 y; 10 males,
12 females) diagnosed with possible iNPH according to
Japanese guidelines [1,2], were enrolled in this study. All
patients or their caregivers consented to CSF protein
analysis following a tap test. This research was approved
by the institutional ethics committee of Kitano Hospital.
Clinical evaluations of gait, cognition, and incontinence
were performed before and 24 h after the CSF tap test,
using the timed up and go test (TUG) [7], iNPH grading
scale (iNPHGS) [8], mini-mental state examination
(MMSE) [9], and frontal assessment battery (FAB) [10].
The patients were divided into two groups according to
their radiological features: the DESH group (10 patients)
and non-DESH ventriculomegaly group (12 patients) [6].
Their demographic features are summarized in Table 1.
None of the patients showed the typical clinical course of
AD, as diagnosed by the National Institute of Neurological
Disease and Communicative Disorders and the Stroke/AD
and Related Disorders Association [11]; however, some pa-
tients had been prescribed acetylcholinesterase (AChE)inhibitors for their dementia. None of the patients had an
obvious history of stroke events indicative of vascular de-
mentia (VD), or showed rigidity implicating other causes
of dementia with lower body Parkinsonism.
CSF sampling and analysis
Lumbar puncture was performed in the L3–L4 or L4–L5
interspace. A 10–30-mL CSF sample was collected and
gently mixed to avoid gradient effects. CSF samples with
cell counts > 5/mm3 were excluded. All CSF samples were
aliquoted and stored in polypropylene tubes at −80°C until
biochemical analysis. For the CSF biomarkers, concentra-
tions of L-PGDS, total tau (t-tau), amyloid beta (Aβ)1–42
(Aβ42), and Aβ1–40 (Aβ40) were estimated. L-PGDS
levels were measured with a standardized in-house
enzyme-linked immunosorbent assay (ELISA) method, as
previously reported [12]. As a control group, the L-PGDS
concentration in samples from 11 patients over the age of
50 was adopted from previously reported data [13]. The
CSF concentration values of Aβs and t-tau were deter-
mined with standardized commercially available ELISA
kits obtained from Immuno Biological Laboratories (IBL,
Gunma, Japan) and Invitrogen (Invitrogen, Camarillo, CA,
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the manufacturer’s protocol. As a control group for Aβs
and t-tau, the CSF from 11 patients over the age of 60 with
Parkinsonism but without radiological ventriculomegaly
was used.
Magnetic resonance imaging
A 3.0-Tesla magnetic resonance imaging (MRI) system
(Achieva Quasar; Philips Medical Systems, Netherlands)
was used. Three-dimensional T1-weighted fast-field echo
images (repetition time [TR], 25 ms; echo time [TE],
2.2 ms; flip angle, 30°; slice thickness, 2.0 mm; intersection
gap, 0.0 mm; field of view, 256 mm; matrix, 256 × 256)
and T2-weighted turbo spin echo images (TR, 5477 ms;
TE, 90 ms; slice thickness, 2.0 mm; intersection gap,
0.0 mm; field of view, 256 mm; matrix, 256 × 256) were
obtained in sections parallel to the anteroposterior com-
missure plane, covering brain regions from the base of the
cerebellum to the vertex. All MRI evaluations were done
by the first author. Evans index was calculated as the max-
imal width of the frontal horns/maximal width of the
inner skull [14]. For approximating DESH severity, we
measured the callosal angle on coronal images perpen-
dicular to the anteroposterior commissure plane on the
posterior commissure, according to an existing protocol
[5]. To evaluate the concomitant ischemic lesions in the
cerebral white matter, we used the age related white mat-
ter change (ARWMC) score [15].
Data analysis
Values are given as means and standard deviations. We












Figure 1 Representative magnetic resonance images of disproportion
upper row) and non-DESH ventriculomegaly (bottom row). Asterisks m
Bars, callosal angles; Arrows, tight medial parietal sulci.the Wilcoxon signed-rank test. Comparisons among the
two groups with ventriculomegaly (DESH and non-DESH;
tap test positive and negative) and the control group were
done by one-way analysis of variance (ANOVA) followed
by post hoc Newman-Keuls multiple comparison test. The
relationships among demographical, radiological, and la-
boratory data were evaluated by Spearman correlation
tests. All statistical analyses were performed using Graph-
Pad Prism 5.01 (GraphPad Software, Inc., La Jolla, CA,
USA), and p < 0.05 was considered statistically significant.
Results
According to the radiological criteria, 10 of the 22 patients
showed typical DESH patterns (Table 1). Representative
DESH and non-DESH patterns on MR images are shown
in Figure 1. Although both groups showed ventriculome-
galy, uneven CSF distribution within the subarachnoid
space was more prominent in DESH patients. Their de-
mographical backgrounds, opening pressures, and the de-
gree of ventriculomegaly as assessed by Evans index were
similar (Table 1). The callosal angle, which is a quasi-
quantitative representative of tight high convexity (an im-
portant factor in DESH), was significantly smaller in
DESH patients compared to in non-DESH patients
(DESH: 79.9 ± 5.5 degrees, non-DESH: 101.2 ± 4.3 degrees,
p = 0.01). Eight out of 10 DESH patients showed a positive
tap test response. Of these patients, 7 underwent shunt
operation, and 6 responded positively to the shunt. On the
contrary, only 5 out of the 12 non-DESH patients were
tap test positive, with 3 undergoing surgery, and 2 being
shunt responders (Table 1). Three of the DESH patients
and 5 of the non-DESH patients were already prescribedcoronal sagittal
ately enlarged subarachnoid-space hydrocephalus (DESH,

























































































































































Figure 2 (See legend on next page.)
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Figure 2 Comparisons of CSF biomarkers among the two ventriculomegalic groups (DESH-based or tap-test-based) and control group.
Central bars: median values, box edges: range of 75 percentile, whisker edges: upper and lower limit values. Significant differences: *p < 0.05,
**p < 0.01, and ***p < 0.001 by one-way analysis of variance followed by post hoc Newman-Keuls multiple comparison tests. Aβ: amyloid beta
DESH: disproportionately enlarged subarachnoid-space hydrocephalus, L-PGDS: lipocalin-type prostaglandin D synthase, t-tau: total tau.
Nishida et al. Fluids and Barriers of the CNS 2014, 11:9 Page 5 of 7
http://www.fluidsbarrierscns.com/content/11/1/9AChE inhibitors for their dementia. Five of the 8 patients
with AChE inhibitor prescriptions responded to the tap
test and 3 of the 5 tap test responders (all with DESH fea-
tures) underwent surgery with successful outcomes.
ARWMC scores seemed to be worse in non-DESH pa-
tients, but this difference was not significant. The TUG
test results were significantly better in the DESH patients
compared to non-DESH (17.8 ± 0.8 s/24.2 ± 0.6 steps,
compared to 29.8 ± 5.7 s/38 ± 5.0 steps, p = 0.04/0.01).
Among the CSF biomarkers, t-tau and L-PGDS were sig-
nificantly lower in the DESH group (t-tau: DESH: 319.9 ±
31.4, non-DESH: 546.2 ± 54.2 pg/mL, p = 0.003; L-PGDS:
DESH: 14.4 ± 1.0, non-DESH: 20.8 ± 2.0 μg/mL, p = 0.01).
The 8 patients with AChE inhibitor prescriptions were
slightly older (with AChE inhibitors: 82.0 ± 1.6 y, without
AChE inhibitors: 73.2 ± 2.0 y, p = 0.007) and had higher
CSF tau levels (with AChE inhibitors: 546.3 ± 76 pg/mL,
without AChE inhibitors: 384.5 ± 40 pg/mL, p = 0.05)
compared to patients without AChE inhibitor prescrip-
tions. However, their tau levels were still low compared
to the institutional values for AD patients (1076.7 ±
608 pg/mL, unpublished data).Table 2 Table of correlation analyses for variables measured in
Age Evans index Callosal an
Evans index −0.049 (0.831)
Callosal angle 0.379 (0.076) −0.188 (0.402)
ARWMC 0.331 (0.143) −0.575 (0.006)* 0.357 (0.103
iNPHGS 0.158 (0.494) −0.177 (0.442) 0.179 (0.426
TUG (s) −0.127 (0.616) 0.138 (0.584) 0.407 (0.094
TUG (step) −0.002 (0.995) −0.001 (0.997) 0.575 (0.013
MMSE −0.133 (0.564) 0.453 (0.040)* −0.289 (0.19
FAB −0.323 (0.153) 0.268 (0.240) −0.192 (0.40
t-tau 0.638 (0.002)** −0.339 (0.133) 0.653 (0.001
Aβ42 0.253 (0.268) 0.045 (0.845) 0.175 (0.437
Aβ40 0.491 (0.024)* −0.160 (0.489) 0.560 (0.007
L-PGDS 0.602 (0.004)** −0.166 (0.471) 0.592 (0.004
TUG (step) MMSE FAB
MMSE −0.530 (0.024)*
FAB −0.345 (0.168) 0.631 (0.002)**
t-tau 0.418 (0.084) −0.456 (0.033) * −0.387 (0.08
Aβ42 0.029 (0.909) 0.416 (0.052) 0.432 (0.051
Aβ40 0.085 (0.738) 0.098 (0.567) 0.262 (0.252
L-PGDS 0.238 (0.342) −0.460 (0.028) * −0.641 (0.00
Spearman r (p value). Significant correlations: *p < 0.05, **p < 0.001. ARWMC: age re
test, MMSE: mini-mental state examination, FAB: frontal assessment battery, t-tau: toTo clarify CSF biomarker differences between the two
ventriculomegalic groups (dichotomized on DESH or on
tap test) and non-ventriculomegalic controls, we recruited
two control groups for L-PGDS and neurodegenerative
markers. As shown in Figure 2, L-PGDS and t-tau dis-
criminated DESH in ventriculomegalic patients, but did
not predict the tap test results. Both t-tau and Aβ concen-
trations were low in the ventriculomegalic groups com-
pared to the control group. However, Aβ concentrations
did not distinguish DESH- or tap-test-based differences.
To elucidate the relationship between clinico-
radiological features and CSF biomarkers further, a correl-
ation analysis was performed. As shown in Table 2, t-tau
and L-PGDS showed a significant positive correlation
(Spearman r = 0.753, p < 0.001). Age and callosal angle
correlated positively with both t-tau (age: Spearman r =
0.638, p < 0.002; callosal angle: r = 0.653, p < 0.001) and
L-PGDS (age: Spearman r = 0.602, p < 0.004; callosal angle:
r = 0.592, p < 0.004). L-PGDS also correlated positively
with ARWMC scores (Spearman r = 0.652, p < 0.001) and
negatively with FAB scores (Spearman r = −0.641, p <
0.004). ARWMC scores were negatively correlated withstudy of twenty two adult patients with ventriculomegaly
gle ARWMC iNPHGS TUG (s)
)
) 0.466 (0.033)*
) 0.206 (0.411) 0.548 (0.019)*
)* 0.132 (0.601) 0.415 (0.087) 0.801 (<0.001)**
1) −0.681 (0.005)** −0.638 (0.002)** −0.290 (0.243)
6) −0.659 (0.001)** −0.564 (0.008) * −0.293 (0.238)
)** 0.490 (0.024)* 0.542 (0.011)* 0.247 (0.324)
) −0.252 (0.271) −0.188 (0.415) −0.062 (0.807)
)* 0.067 (0.774) −0.024 (0.918) −0.066 (0.795)




) 0.530 (0.014)* 0.667 (0.001)**
4)** 0.753 (<0.001)** −0.058 (0.801) 0.357 (0.106)
lated white matter change, iNPHGS: iNPH grading scale, TUG: timed up and go
tal tau, Aβ: amyloid beta, L-PGDS: lipocalin-type prostaglandin D synthase.
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man r = −0.659, p < 0.001) scores. Compared to other
CSF biomarkers, Aβs were not correlated with clinico-
radiological features at the p < 0.005 level.Discussion
In this study, we confirmed the usefulness of MRI-based
(DESH-based) diagnostic schemes and recognized the
lower success rate of tap tests in non-DESH ventriculo-
megaly. As for the CSF biomarkers, we confirmed that
patients with DESH-type iNPH had significantly lower
L-PGDS and t-tau levels compared to non-DESH. More-
over, we recognized the positive correlation between
L-PGDS and t-tau, both of which correlated positively with
the callosal angle and age of ventriculomegalic patients.
In addition to our small sample size, this study, similar
to previous clinical studies on iNPH, has several further
limitations that were related to the patients’ comorbidi-
ties [16]. We included 8 patients who had been pre-
scribed AChE inhibitors in this study, yet their CSF t-tau
levels were still low compared to that of full-blown AD
patients. Another problem related to comorbidity was the
diagnosis of VD, which was rather difficult when the pa-
tients did not have a clear history of stroke, but did have
severe small vessel disease with ventriculomegaly accord-
ing to MRI. In this study, we used the patients’ ARWMC
scores [15] instead of several other VD diagnostic criteria
[17] to represent their potential VD comorbidity. Further-
more, true iNPH patients have undergone successful
shunt operations, yet many of the patients with ventriculo-
megaly do not reach the operation room even after a posi-
tive tap test due to comorbidities and social problems. In
this regard, we arbitrarily grouped our patients using a
DESH-based scheme, which was supported by the results
of subsequent correlation analyses.
Several reports have suggested that the CSF biomarker
t-tau plays a role in the neurodegenerative mechanisms
underlying iNPH development. Tau is a microtubule-
associated protein that promotes and stabilizes micro-
tubule assembly, and is primarily located in the axons of
neuronal cells [18,19]. Increases in CSF t-tau indicate
the severity of neuronal damage and loss [20]. CSF t-tau
increases with age and the severity of clinical symptoms
in iNPH, and tends to be lower in patients with good
cognitive recovery after shunt surgery [21,22]. According
to our study and several previous studies on iNPH, t-tau
levels in iNPH were usually around the normal range,
and were significantly lower than that of AD and VD pa-
tients [23-25]. Preoperative high lumber CSF t-tau might
be an ominous sign for shunt candidates.
In regards to L-PGDS, its decrease has been attributed
to arachnoidopathy (i.e., loss of arachnoid cells produ-
cing L-PGDS) particularly in secondary NPH aftersubarachnoid hemorrhage [13,26]. In our study, de-
creased L-PGDS was correlated with a narrow callosal
angle, which is a feature of an uneven CSF distribution
in DESH-type iNPH. However, whether DESH is caused
by arachnoidopathy is still under discussion. Moreover,
it seemed rather paradoxical that patients with low
L-PGDS levels showed high cognitive function despite
the severe arachnoidopathy. Compared to previously re-
ported control groups, L-PGDS levels in our DESH
group appeared normal, while the levels in the non-
DESH group were significantly higher. These findings
may suggest that the non-DESH patients were simply in
a later stage of hydrocephalus progression (e.g., white
matter damage), and thus had less of a chance to im-
prove with either the tap test or shunting [27].
L-PGDS is considered a dual functional protein, i.e., it
acts as a prostaglandin D2-producing enzyme and as a
lipophilic ligand-binding protein [28]. Its lipophilic na-
ture allows it to function as a chaperone for preventing
the formation of neurotoxic agents, such as Aβ fibrils
[29]. In this regard, we initially expected there to be a re-
lationship between CSF Aβ and L-PGDS. However, both
DESH and non-DESH ventriculomegaly groups showed
similar low levels of Aβs compared to the control groups
without ventriculomegaly. Instead, we found a significant
correlation between CSF t-tau and L-PGDS. Tau is a
hydrophilic protein, yet its neurotoxic aggregation cer-
tainly occurs in AD and in several tauopathies [18]. Tau
protein is greatly charged and has the capacity to inter-
act with many partners; its interaction with L-PGDS,
however, needs further investigation.Conclusions
In summary, we found two potential CSF biomarkers,
t-tau and L-PGDS, for distinguishing DESH-type iNPH
from non-DESH type. Moreover, their concomitant de-
crease and positive relationship could indicate an un-
known mechanism underlying iNPH development. In
addition, we propose L-PGDS as a surrogate marker of
DESH features, white matter damage, and frontal lobe
dysfunction. The same two markers did not predict tap
test results.Abbreviations
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